Skip to content

Clinical Evaluation of Safety & efficacy of Mensta (WHS/2004/1) in Menstural Cramps.

Open clinical trial to evaluate the efficacy of WHS/2004/1 in Dysmenorrhoea & Menstrual Irregularities.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012629
Enrollment
50
Registered
2018-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N945- Secondary dysmenorrhea

Interventions

Intervention1: Dabur Mensta (WHS/2004/1): Studied formulation is composed of Saracs Indica, Santlllum album, Woodford/a frutlcoa, Trlphtla, Zingiber officinale, Mangifera indica, Cyperus rotundus, Cum

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged between 15-45 years (females in the reproductive age group). 2. Females presenting with DYSMENORRHEA with or without any of the following symptoms associated with menstruation a. Any kind of pain like headache, backache abdominal pain,bodyache b. Nausea and vomiting c. Weakness d. Psychological symptoms- like anxiety, stress, depression, irritability, restlessness e. Irregular cycles 3. Willingness to participate in the trial and to come for regular follow up as and when required. 4. Readiness to sign Informed Consent Form

Exclusion criteria

Exclusion criteria: 1. Patients nursing or pregnant women. 2. Patients having organic causes of pain and menstrual abnormalities like uterine myeloma, adenomyosis, polyps, fibroids, endometriosis etc. 3. Patients suffering from systemic or metabolic disorders like pituitary disease, diabetes mellitus, thyroid dysfunction and coagulation-disorders. 4. Patients having any other kind of chronic disease like respiratory or cardiac problems, HIV. 5. Subjects not willing to sign informed consent. 6. Patients participating in any other clinical study.

Design outcomes

Primary

MeasureTime frame
Relief from symptoms of DysmenorrheaTimepoint: Evaluations were done at 2 week intervals for 12 weeks

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Arun Gupta

Dabur India Limited

arun.gupta@dabur.com9910200255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026